Kymera Therapeutics (NASDAQ:KYMR) Trading 4.5% Higher

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price shot up 4.5% during trading on Thursday . The stock traded as high as $35.32 and last traded at $35.28. Approximately 318,646 shares changed hands during trading, a decline of 57% from the average session volume of 742,994 shares. The stock had previously closed at $33.76.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their target price on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Piper Sandler increased their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Truist Financial lifted their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Bank of America cut shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.89.

Kymera Therapeutics Trading Down 3.3 %

The business’s fifty day moving average price is $39.16 and its 200-day moving average price is $27.87.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.19. The business had revenue of $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The company’s quarterly revenue was up 197.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.60) EPS. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.13 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the completion of the sale, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the transaction, the insider now directly owns 4,925,812 shares of the company’s stock, valued at $211,071,044.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce Booth sold 139,255 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the completion of the sale, the director now directly owns 828,830 shares of the company’s stock, valued at $35,001,490.90. The disclosure for this sale can be found here. Insiders have sold 484,051 shares of company stock worth $19,924,711 over the last 90 days. 16.67% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors have recently modified their holdings of KYMR. Raymond James & Associates boosted its position in Kymera Therapeutics by 1.9% in the fourth quarter. Raymond James & Associates now owns 16,781 shares of the company’s stock worth $419,000 after purchasing an additional 317 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Kymera Therapeutics by 1.3% in the 4th quarter. Legal & General Group Plc now owns 33,154 shares of the company’s stock worth $828,000 after buying an additional 424 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Kymera Therapeutics by 2.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,940 shares of the company’s stock worth $584,000 after buying an additional 524 shares during the last quarter. Congress Asset Management Co. MA grew its position in Kymera Therapeutics by 1.2% during the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after buying an additional 533 shares during the period. Finally, American International Group Inc. increased its holdings in Kymera Therapeutics by 3.7% during the second quarter. American International Group Inc. now owns 17,698 shares of the company’s stock worth $348,000 after buying an additional 638 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.